|

REGN5678 Clinical Trials

4 actively recruiting trials across 3 locations

No change since May 2026

Also known as: Nezastomig, PYLARIFY

Pipeline

Phase 1: 1Phase 1/2: 3

Top Sponsors

  • Regeneron Pharmaceuticals2
  • M.D. Anderson Cancer Center2

Indications

  • Cancer4
  • Prostate Cancer2
  • Radical Prostatectomy1
  • Clear Cell Renal Cell Carcinoma (ccRCC)1
  • Metastatic Castration-resistant Prostate Cancer, mCRPC1

Houston, Texas2 trials

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

The University of Texas M. D. Anderson Cancer Center

Phase 1
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

M D Anderson Cancer Center

Phase 1/2

Gilbert, Arizona1 trial

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Banner MD Anderson Cancer Center

Phase 1/2

Palo Alto, California1 trial

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

Stanford University Medical Center - Blake Wilbur Drive

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.